Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria
| Autor: | Abhishek Kavati, Vincent J. Willey, Judith J. Stephenson, Liya Wang, Debra A. Wertz, Jonathan A. Bernstein, Xuehua Ke, Benjamin Ortiz, Brandee Paknis, Qing Huang, Lisa A. Beck |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Health plan Treatment response Pediatrics medicine.medical_specialty Urticaria Omalizumab 03 medical and health sciences 0302 clinical medicine medicine Humans In patient Aged Retrospective Studies business.industry Medical record General Medicine Middle Aged 030104 developmental biology 030228 respiratory system Chronic Disease Female Chronic idiopathic urticaria Database research business Cohort study medicine.drug |
| Zdroj: | Current Medical Research and Opinion. 34:35-39 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1080/03007995.2017.1395732 |
| Popis: | To examine treatment patterns, treatment response, and demographic and clinical characteristics of patients with chronic idiopathic urticaria (CIU) newly initiated on omalizumab therapy in real-world practice in the US.This retrospective observational cohort study used US claims data from the HealthCore Integrated Research Database (HIRDThis study consisted of 88 patients with a mean (SD) age of 43.4 (± 13.46) years, 68.2% were female, and 36 patients had ≥18 months post-index eligibility. Among 69 patients with documented index dose, 75.4% received omalizumab 300 mg and 69.6% remained on index dose throughout follow-up. For 52 patients with documented index dosing frequency, 96.2% had every 4-week dosing frequency. Among 86 patients with omalizumab documentation, 83.7% reported CIU improvement after omalizumab initiation and 24.4% discontinued omalizumab. For all patients, the proportion using oral corticosteroids (OCS) decreased pre- to post-index (52.3% vs 39.8%). Similar results were observed for patients with ≥18 months post-index eligibility.In this real-world analysis, the majority of patients remained on omalizumab for ≥12 months, and had a positive response. OCS use decreased following omalizumab initiation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|